pharma news today glp-1 obesity Market GLP-1 agonists and changes in

For example: A weight-loss program is eligible only if its prescribed to treat a specific condition, like obesity or heart disease

FASEB J (2010) 24(10):39609.10.1096/fj.10-158105 69 MartinBDotsonCDShinYKJiSDruckerDJMaudsleySet alModulation of taste sensitivity by GLP-1 signaling in taste buds

Common signs include: Redness at the injection site Mild swelling or raised bumps Itching or slight tenderness Warmth in the area These reactions are considered relatively common with injectable medications and usually do not mean the treatment needs to be stopped

doi:10.1056/NEJMoa2500969 Wharton S, Aronne LJ, Stefanski A, et al

Published online February 28, 2019 DOI: 12,359 View 183 Download 34 Web of Science 35 Crossref Abstract PDFPubReader ePub Background Impaired diastolic heart function has been observed in persons with non-alcoholic fatty liver disease (NAFLD) and/or with type 2 diabetes mellitus (T2DM)

That's the scale of change that moves metabolic markers, not just the number on the scale